Compare AVLN & TRUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | TRUP |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2026 | 2014 |
| Metric | AVLN | TRUP |
|---|---|---|
| Price | $33.84 | $24.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.80 |
| AVG Volume (30 Days) | 175.5K | ★ 389.5K |
| Earning Date | N/A | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 295.65 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $1,439,305,000.00 |
| Revenue This Year | N/A | $11.79 |
| Revenue Next Year | N/A | $8.83 |
| P/E Ratio | ★ N/A | $91.85 |
| Revenue Growth | N/A | ★ 11.95 |
| 52 Week Low | $24.90 | $21.16 |
| 52 Week High | $40.17 | $46.98 |
| Indicator | AVLN | TRUP |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 34.88 |
| Support Level | $34.22 | $24.26 |
| Resistance Level | $40.08 | $26.92 |
| Average True Range (ATR) | 1.96 | 1.16 |
| MACD | -0.39 | -0.76 |
| Stochastic Oscillator | 9.89 | 6.19 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions. Geographically, the company operates in United States, which derives maximum revenue; and Canada and Others.